We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

84 hedge funds and large institutions have $13.9M invested in Definium Therapeutics in 2023 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 13 increasing their positions, 12 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

905% more call options, than puts

Call options by funds: $9.99M | Put options by funds: $994K

11% more capital invested

Capital invested by funds: $12.6M → $13.9M (+$1.34M)

8% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 12

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.28% less ownership

Funds ownership: 10.36% → 10.08% (-0.28%)

5% less funds holding

Funds holding: 88 → 84 (-4)

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

Holders
84
Holders Change
-4
Holders Change %
-4.55%
% of All Funds
1.32%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
13
Reduced
12
Closed
11
Calls
$9.99M
Puts
$994K
Net Calls
+$9M
Net Calls Change
+$217K

Top Buyers

1
CAM
Cresset Asset Management
Illinois
+$550K
2
BlackRock
BlackRock
New York
+$350K
3
CIC
Cornercap Investment Counsel
Georgia
+$195K
4
Group One Trading
Group One Trading
Illinois
+$173K
5
Millennium Management
Millennium Management
New York
+$161K

Top Sellers

1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$847K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$800K
3
Renaissance Technologies
Renaissance Technologies
New York
-$66.5K
4
Citadel Advisors
Citadel Advisors
Florida
-$51K
5
PCM
Prelude Capital Management
New York
-$39.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$39.9K +$9.08K +2,632 +31%
Wolverine Trading
27
Wolverine Trading
Illinois
$37.3K +$37.2K +10,770 New
Barclays
28
Barclays
United Kingdom
$32.7K – – –
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$27K +$9.74K +2,824 +61%
Deutsche Bank
30
Deutsche Bank
Germany
$20K -$8.31K -2,408 -30%
Osaic Holdings
31
Osaic Holdings
Arizona
$13.5K -$1.07K -311 -8%
TWC
32
TD Waterhouse Canada
Ontario, Canada
$7.92K +$3.66K +1,062 +144%
MFT
33
Moisand Fitzgerald Tamayo
Florida
$7.14K +$6.9K +2,000 New
CA
34
Crewe Advisors
Utah
$7.14K – – –
Carson Wealth (CWM LLC)
35
Carson Wealth (CWM LLC)
Nebraska
$7K – – –
National Bank of Canada
36
National Bank of Canada
Quebec, Canada
$5.36K -$159 -46 -3%
UBS Group
37
UBS Group
Switzerland
$2.68K -$31.2K -9,050 -92%
EDRH
38
Edmond de Rothschild Holding
Switzerland
$2.38K – – –
CCA
39
Column Capital Advisors
Indiana
$2.18K – – –
PA
40
Parallel Advisors
California
$1.94K – – –
TIM
41
Tortoise Investment Management
New York
$1.43K – – –
AFG
42
Albion Financial Group
Utah
$1.15K – – –
EL
43
EMFO LLC
Florida
$1.07K – – –
Wells Fargo
44
Wells Fargo
California
$875 +$59 +17 +7%
KTC
45
Kistler-Tiffany Companies
Pennsylvania
$779 – – –
NA
46
NewEdge Advisors
Louisiana
$528 +$459 +133 +887%
FFA
47
Farther Finance Advisors
California
$357 – – –
PGAM
48
Princeton Global Asset Management
New Jersey
$357 – – –
AF
49
Allworth Financial
California
$236 – – –
AF
50
Arrow Financial
New York
$236 – – –
1
2
3 4

DFTX Hedge Fund Activity: Q2 2023 in Review

84 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q2 2023, worth a combined $13.9M — up 11% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of DFTX and 8 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 13 added.

The largest buyer was Cresset Asset Management, opening a new position worth an estimated $550K. The largest seller was Alyeska Investment Group, cutting an estimated $847K.

  • 84 institutional investors held Definium Therapeutics (DFTX) as of Q2 2023, down from 88 in Q1 2023.
  • Funds reported $13.9M of Definium Therapeutics stock for Q2 2023, up 11% quarter-over-quarter.
  • 8 funds opened new Definium Therapeutics positions in Q2 2023 and 11 closed out, a net change of -3 holders.
  • The largest Definium Therapeutics buyer in Q2 2023 was Cresset Asset Management, an estimated $550K added.
  • The largest Definium Therapeutics seller in Q2 2023 was Alyeska Investment Group, an estimated $847K sold.

Based on aggregated 13F filings for Q2 2023.